Logo for Iterum Therapeutics plc

Iterum Therapeutics Investor Relations Material

Latest events

Logo for Iterum Therapeutics plc

Q3 2024

Iterum Therapeutics
Logo for Iterum Therapeutics

Q3 2024

14 Nov, 2024
Logo for Iterum Therapeutics

FDA Announcement

28 Oct, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Iterum Therapeutics plc

Access all reports
Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing novel anti-infective therapies. The company is working on next-generation oral and intravenous antibiotics designed to combat infections caused by multi-drug resistant pathogens, which are a growing global health concern. Iterum's lead product candidate, sulopenem, is a novel penem antibiotic that has shown potent activity against a broad spectrum of bacteria, including strains that are resistant to other antibiotics. Iterum Therapeutics is headquartered in Dublin, Ireland, and its shares are listed on the NASDAQ.